ORIC Pharmaceuticals, Inc.: Revision history

20 August 2022

• curprev 11:0211:02, 20 August 2022 95.149.241.133 talk 1,047 bytes +11 No edit summary undo

13 August 2022

• curprev 16:1916:19, 13 August 2022 109.180.50.163 talk 1,036 bytes +15 No edit summary undo

30 July 2022

• curprev 17:2617:26, 30 July 2022 172.18.0.2 talk 1,021 bytes +1,021 Created page with "ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penet..."